According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules

According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical research community in order to develop an appropriate intervention to treat the illness caused by the SARS-CoV-2 virus.

 

To order this 170+ page report, which features 55+ figures and 80+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

 

The USD 1.6 billion (by 2030) financial opportunity within the fragment-based drug discovery market has been analyzed across the following segments:

  • Type of Screening Technique Used
  • X-ray Crystallography
  • Nuclear Magnetic Resonance
  • Surface Plasmon Resonance
  • Other Screening Techniques

 

  • Type of Service Offered
  • Library Screening
  • Fragment Screening
  • Fragment Optimization

 

  • End User
  • Industry Players
  • Non-Industry Players

 

  • Key geographical regions
  • North America (US and Canada)
  • Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
  • Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)

 

The “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • 2bind
  • Charles River Laboratories
  • ChemAxon
  • ComInnex
  • Creative Biolabs
  • Creative Biostructure
  • CRELUX
  • Domainex
  • Evotec
  • Red Glead Discovery
  • SARomics Biostructures
  • Shanghai ChemPartner
  • Sygnature Discovery
  • Vernalis Research

 

Table of Contents

 

 

 

Press Release: Variation 3 (Format 4)

 

  1. Preface

    2. Executive Summary

  2. Introduction

  3. Current Market Landscape

  4. Company Profiles: Fragment-based Drug Discovery Library and Service Providers

  5. Partnerships and Collaborations

  6. Key Acquisition Targets

  7. Company Competitiveness Analysis

  8. Cost Saving Analysis

  9. Market Forecast and Opportunity Analysis

  10. Executive Insights

 

  1. Concluding Remarks

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Accordingto experts in this field, fragment-based drug discovery solutions havefacilitated the identification of viable pharmacological leads againstotherwise hard to target biomolecules. In fact, many service provider companiesare offering fragment libraries and support to the medical research communityin order to develop an appropriate intervention to treat the illness caused bythe SARS-CoV-2 virus.

 

To order this 170+ pagereport, which features 55+ figures and 80+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

 

The USD 1.6 billion (by 2030) financial opportunity within thefragment-based drug discovery market has been analyzed across the followingsegments:

§ Type of ScreeningTechnique Used

§ X-ray Crystallography

§ Nuclear Magnetic Resonance

§ Surface PlasmonResonance

§ Other ScreeningTechniques

 

§  Type of Service Offered

§ Library Screening

§ Fragment Screening

§ Fragment Optimization

 

§ End User

§ Industry Players

§ Non-Industry Players

 

§ Key geographicalregions

§ North America (US andCanada)

§ Europe (UK, France,Germany, Spain, Italy, and rest of Europe)

§ Asia-Pacific (China,Japan, India, and rest of Asia-Pacific / rest of the world)

 

The Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:

§  2bind

§  Charles River Laboratories

§  ChemAxon

§  ComInnex

§  Creative Biolabs

§  Creative Biostructure

§  CRELUX

§  Domainex

§  Evotec

§  Red Glead Discovery

§  SARomics Biostructures

§  Shanghai ChemPartner

§  Sygnature Discovery

§  Vernalis Research

 

Table of Contents

 

 

 

Press Release:Variation 3 (Format 4)

 

1. Preface

2. Executive Summary


3. Introduction

4. Current Market Landscape

5. Company Profiles: Fragment-based Drug Discovery Library and ServiceProviders 

6. Partnerships and Collaborations

7. Key Acquisition Targets

8. Company Competitiveness Analysis

9. Cost Saving Analysis

10. Market Forecast and Opportunity Analysis

11. Executive Insights

 

12. Concluding Remarks

 

13. Appendix 1: Tabulated Data

 

14. Appendix 2: List of Companies and Organizations

 

Topurchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com